Skip to main content
. Author manuscript; available in PMC: 2009 Feb 1.
Published in final edited form as: Biochem Biophys Res Commun. 2007 Nov 29;366(1):1–7. doi: 10.1016/j.bbrc.2007.11.077

Fig. 3.

Fig. 3

Detection of antibodies against GAD65 and its sub-fragments in SPS and control sera. Antibody titers to Ruc-antigen fusions for full-length GAD65 (FL) and five GAD65 sub-fragments (Δ1, Δ2, Δ3, and Δ5), GAD67-Δ5, tyrosine hydroxylase (TyrH), GABA transaminase (GT) and CSAD-Δ5 were determined in duplicate from 40 sera samples (1–40) using LIPS. The average titer values for each serum were log10 transformed and the samples were rank ordered from highest to lowest based on the antibody titer to full-length GAD65. Titer levels were color-coded as indicated by the log10 scale on the left, in which signal intensities range from red to green indicating high and low titers, respectively. SPS positive samples are above the black line. At the right is the clinical assessment profile including overall severity scale (1–3; mild, moderate, severe), number of sites affected (1–6) and startle response (1–7). No correlation was found between any of the autoantibody titers and these measures of disease severity.